Anavex Life Sciences Corp
NASDAQ:AVXL
Anavex Life Sciences Corp
NASDAQ:AVXL
Price:
4.525
USD
-3.72%
Market Closed
Market Cap:
$404.3m
Relative Value
The Relative Value of one
AVXL
stock under the Base Case scenario is
29.327
USD.
Compared to the current market price of 4.525 USD,
Anavex Life Sciences Corp
is
Undervalued by 85%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AVXL
Relative Value
Base Case
29.327
USD
Undervaluation 85%
Multiples Across Competitors
AVXL Competitors Multiples
Anavex Life Sciences Corp Competitors
Anavex Life Sciences Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Anavex Life Sciences Corp
NASDAQ:AVXL
|
400.4m USD | 0 | -8.5 | -5.6 | -5.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.8B USD | 6.7 | 169.8 | 16.4 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD | 5.2 | 26.5 | 18.9 | 18.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.3B USD | 6.1 | 21.9 | 14.8 | 14.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120B USD | 10.2 | 32.6 | 24 | 25.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD | 5.5 | 17.6 | 14.9 | 17 | |
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD | 3.9 | 20.1 | 13.4 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 14.3 | 33.6 | 57.3 | 58.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
